SLC1A4在不同恶性肿瘤中作用的研究进展

doi:10.11904/j.issn.1002-3070.2026.01.010

摘要/Abstract

摘要： 溶质载体家族1成员4(solute carrier family 1 member 4,SLC1A4)是一种中性氨基酸转运蛋白,在维持细胞内氨基酸稳态、氧化还原过程以及能量代谢中发挥关键作用。作为铁死亡相关基因,SLC1A4的异常表达与多种恶性肿瘤的不良预后密切相关。SLC1A4蛋白通过调控半胱氨酸的摄取与谷胱甘肽合成,降低肿瘤细胞的铁死亡敏感性,进而促进化疗耐药的形成与肿瘤免疫微环境重塑。本文就SLC1A4基因在不同恶性肿瘤中的作用及机制进行综述,旨在为恶性肿瘤的诊断以及治疗提供新的潜在靶点。

关键词: 溶质载体家族1成员4, 恶性肿瘤, 作用机制, 靶向治疗, 铁死亡相关基因

Abstract: Solute carrier family 1 member 4(SLC1A4),a neutral amino acid transporter,plays a crucial role in maintaining intracellular amino acid homeostasis,redox processes,and energy metabolism.As a ferroptosis-related gene,SLC1A4 expression is associated with poor prognosis in various malignant tumors.The SLC1A4 protein reduces the sensitivity of ferroptosis in tumor cells by regulating the uptake of cysteine and glutathione synthesis,thereby promoting the formation of chemotherapy resistance and remodeling the tumor immune microenvironment.This article reviews the role and mechanism of SLC1A4 gene in different malignant tumors,aiming to provide new targets for the diagnosis and treatment of malignant tumors.

Key words: solute carrier family 1 member 4, malignant tumors, mechanism of action, targeted therapy, ferroptosis-related genes

中图分类号:

R730.7

蔡意好, 赵俊皓, 赵金璐, 刘明. SLC1A4在不同恶性肿瘤中作用的研究进展[J]. 实用肿瘤学杂志, 2026, 40(1): 69-74.

CAI Yihao, ZHAO Junhao, ZHAO Jinlu, LIU Ming. Research progress on the role of SLC1A4 in different malignant tumors[J]. Journal of Practical Oncology, 2026, 40(1): 69-74.

参考文献

1 Wu HL,Luo PF,Yan LY,et al.Research progress of amino acid transporter SLC1 family as tumor therapeutic targets [J].HJBM,2024,14(2):157-165.
2 Scalise M,Console L,Cosco J,et al.ASCT1 and ASCT2:brother and sister? [J].SLAS Discov,2021,26(9):1148-1163.
3 Lyda B,Leary G,Farnsworth J,et al.Discovery and synthesis of hydroxy-l-proline blockers of the neutral amino acid transporters SLC1A4(ASCT1)and SLC1A5(ASCT2)[J].Molecules,2024,29(10):2330-2349.
4 Liu Y,Xiong H,Yan C,et al.Bioinformatic analysis of the prognostic value of a panel of six amino acid transporters in human cancers [J].Cell J,2023,25(9):613-624.
5 Mohamed F,Ghattas M,Almansoori T,et al.Novel compound heterozygous variants(c.971delA/c.542C＞T)in SLC1A4 causes spastic tetraplegia,thin corpus callosum,and progressive microcephaly:a case report and mutational analysis [J].Front Pediatr,2023,11:1183574.
6 Stehantsev P,Stetsenko A,Nemchinova M,et al.A structural view onto disease-linked mutations in the human neutral amino acid exchanger ASCT1 [J].Comput Struct Biotechnol J,2021,19:5246-5254.
7 Pujol-Giménez J,Mirzaa G,Blue E,et al.Dominant-negative variant in SLC1A4 causes an autosomal dominant epilepsy syndrome [J].Ann Clin Transl Neurol,2023,10(6):1046-1053.
8 Odeh M,Sajrawi C,Majcher A,et al.A new type of blood-brain barrier aminoacidopathy underlies metabolic microcephaly associated with SLC1A4 mutations [J].Brain,2024,147(11):3874-3889.
9 Sarigecili E,Bulut F,Anlas O.A rare cause of microcephaly,thin corpus callosum and refractory epilepsy due to a novel SLC1A4 gene mutation [J].Clin Neurol Neurosurg,2022,218:107283.
10 Elazar D,Alvarez N,Drobeck S,et al.SLC1A4 and serine homeostasis:Implications for neurodevelopmental and neurodegenerative disorders [J].Int J Mol Sci,2025,26(5):2104.
11 Xue XF,Wang MY,Cui JT,et al.Glutathione metabolism in ferroptosis and cancer therapy [J].Cancer Lett,2025,621:217697.
12 Zhao J,Ma YB,Xia RH,et al.Skullcapflavone II inhibits SLC1A4-mediated L-serine uptake and promotes mitochondrial damage in gastric cancer [J].Adv Sci(Weinh),2025:e17225.
13 Chakraborty A,Patnaik J,Sinha A,et al.In silico analysis shows slc1a4 as a potential target of hsa-mir-133a for regulating glutamine metabolism in gastric cancer [J].Int J Biol Macromol,2024,282(Pt 5):136974.
14 Huang Y,Zou YM,Sun W,et al.Screening ferroptosis related genes influencing prognosis of gastric adenocarcinoma through bioinformatics analysis [J].Acta Med Univ Sci Technol Huazhong,2021,50(5):597-602.
15 Zheng J,Gong J.SLC1A4 promotes malignant transformation of hepatocellular carcinoma by activating the Akt signaling [J].Anal Cell Pathol(Amst),2025,2025:1115184.
16 Peng X,Chen R,Cai S,et al.SLC1A4:A powerful prognostic marker and promising therapeutic target for HCC [J].Front Oncol,2021,11:650355.
17 Yuan S,Tanzeel Y,Tian X,et al.Global analysis of HBV-mediated host proteome and ubiquitylome change in HepG2.2.15 human hepatoblastoma cell line [J].Cell Biosci,2021,11(1):75.
18 Zhang L,Ren B,Wei F,et al.Ferroptosis regulator NOS2 is closely associated with the prognosis and cell malignant behaviors of hepatoblastoma:a bioinformatic and in vitro study [J].Front Oncol,2023,13:1228199.
19 Wang H,Yang C,Jiang Y,et al.A novel ferroptosis-related gene signature for clinically predicting recurrence after hepatectomy of hepatocellular carcinoma patients [J].Am J Cancer Res,2022,12(5):1995-2011.
20 Parker S,Amendola C,Hollinshead K,et al.Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer [J].Cancer Discov,2020,10(7):1018-1037.
21 Wong CH,Li CH,He Q,et al.Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma [J].Cancer Lett,2020,477:1-9.
22 Meira W,Daher B,Parks SK,et al.A cystine-cysteine intercellular shuttle prevents ferroptosis in xCT(KO)pancreatic ductal adenocarcinoma cells [J].Cancers(Basel),2021,13(6):1434.
23 Lin Z,Yang S,Qiu Q,et al.Hypoxia-induced cysteine metabolism reprogramming is crucial for the tumorigenesis of colorectal cancer [J].Redox Biol,2024,75:103286.
24 Krys D,Mattingly S,Glubrecht D,et al.PET imaging of L-Type amino acid transporter(LAT1)and cystine-glutamate antiporter(x(c)(-))with [(18)F]FDOPA and [(18)F]FSPG in breast cancer models [J].Mol Imaging Biol,2020,22(6):1562-1571.
25 Wu Z,Tang Y,Yu H,et al.The role of ferroptosis in breast cancer patients:a comprehensive analysis [J].Cell Death Discov,2021,7(1):93.
26 Li Q,Liu H,Jin Y,et al.Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes [J].Comput Biol Med,2023,165:107370.
27 Su LD,Peng JM,Bao YX,et al.Study on the role of low expression SLC1A4 in cisplatin resistance in ovarian cancer [J].Chin J Mod Appl Pharm 2024,41(9):1204-1213.
28 Xing Y,Liu Z,Ma X,et al.Targeted metabolomics analysis identified the role of FOXA1 in the change in glutamate-glutamine metabolic pattern of BaP malignantly transformed 16HBE cells [J].Toxicol Appl Pharmacol,2023,461:116402.
29 Pang S,Zhao S,Dongye Y,et al.Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma [J].Cell Biol Int,2024,48(6):777-794.
30 White M,Lin C,Rajapakshe K,et al.Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer [J].Mol Cancer Res,2017,15(8):1017-1028.
31 Ryan R,Holst J.Regulation of SLC1A4 and SLC1A5 in prostate cancer-letter [J].Mol Cancer Res,2018,16(11):1809-1810.
32 White M,Frigo D.Regulation of SLC1A4 and SLC1A5 in prostate cancer-response [J].Mol Cancer Res,2018,16(11):1811-1812.
33 Shao YF,Yu QY,Zhu JF,et al.Construction and mechanistic exploration of a ferroptosis related gene based prognostic model for cisplatin resistance in bladder cancer [J].Comput Methods Biomech Biomed Engin,2025:1-20.
34 Zhang S,Huang F,Wang Y,et al.NAT10-mediated mRNA N(4)-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia [J].Nat Cell Biol,2024,26(12):2168-2182.
35 Feng XY,Qin YF,Yuan Y,et al.Machine learning combined with immune cell infiltration to analyze the mechanism of ferroptosis in chronic myeloid leukemia [J].Biotechnology,2024,34(6):696-706.
36 Park HY,Lee SB,Yoo HY,et al.Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma [J].Oncotarget,2016,7(52):86433-86445.
37 Li Z,Zhang X,Jin Q,et al.Development of a macrophage-related risk model for metastatic melanoma [J].Int J Mol Sci,2023,24(18):13752.

[1]	全昕竹, 潘宇飞, 王红阳, 董立巍. 蛋白质糖基化修饰在肝细胞癌中的功能和临床意义[J]. 实用肿瘤学杂志, 2026, 40(1): 56-63.
[2]	陈铭睿, 韩颖颖, 林玲, 段洋洋, 刘海峰, 刘韵, 蔡波, 徐红, 李鑫林. 2020年南通市城区恶性肿瘤流行现状及2011—2020年变化趋势分析[J]. 实用肿瘤学杂志, 2025, 39(6): 500-506.
[3]	赵志龙, 侯俊明. 细胞外基质在胰腺癌中的作用机制及治疗靶点研究进展[J]. 实用肿瘤学杂志, 2025, 39(6): 535-541.
[4]	蔡医擎, 代恩勇. 胃癌分子靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2025, 39(6): 542-550.
[5]	李吉, 陈杨, 张茂镕, 杨昭, 唐娴, 文洪梅. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
[6]	周素霞, 许志华, 郭淑玲, 范宁, 徐莉立. 2014—2021年青海省肿瘤登记地区恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(5): 381-387.
[7]	刘洋, 王颖, 马祥, 宋家宝, 刘大民, 陈丽莉. 2021年辽宁省营口市城市居民恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2025, 39(5): 400-404.
[8]	代晓泽, 马玉霞, 李雨婷, 齐笑晴, 祝天岑, 穆慧娟, 刘辉. 2014—2020年辽宁省阜新市城市居民恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(4): 278-283.
[9]	祝天岑, 礼彦侠, 任方晗, 代晓泽, 刘洋, 穆慧娟. 2021年辽宁省肿瘤登记地区恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2025, 39(4): 294-300.
[10]	李吉, 张茂镕, 杨昭, 文洪梅, 伍福仙, 李云涛. 2020年云南省昆明市肿瘤登记地区恶性肿瘤发病和死亡特征及2016—2020年趋势分析[J]. 实用肿瘤学杂志, 2025, 39(3): 169-176.
[11]	文小焱, 陈俐. 2010年和2020年四川省30岁及以上人群恶性肿瘤疾病负担比较分析[J]. 实用肿瘤学杂志, 2025, 39(1): 1-6.
[12]	陈茂森, 陈杨, 石青萍, 邵英, 唐娴, 任思颖, 文洪梅. 2020年云南省恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2024, 38(5): 283-288.
[13]	苏锋, 梁磊, 邓英, 张同蕾, 王艳平. 2016—2020年陕西省安康市恶性肿瘤流行特征和变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(5): 300-305.
[14]	何佳颖, 朱津丽, 贾凯旋, 杨佩颖. IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 330-335.
[15]	刘丽莉, 张雪云, 张雷. 2020—2022年第一师阿拉尔市恶性肿瘤发病分析[J]. 实用肿瘤学杂志, 2024, 38(4): 246-253.